Verona Pharma PLC Appointment of Vikas Sinha as Non-Executive Director

 
TIDMVRP 
 
Verona Pharma plc 
 
                      ("Verona Pharma" or the "Company") 
 
             Appointment of Vikas Sinha as Non-Executive Director 
 
12 September 2016, Cardiff - Verona Pharma plc (AIM: VRP), a drug development 
company focused on first-in-class medicines to treat respiratory diseases, 
today announces the appointment of Vikas Sinha to the Board of Verona Pharma as 
a Non-Executive Director, with immediate effect. 
 
Vikas (aged 53) has over 20 years of experience working in senior finance roles 
in the life sciences industry. He is currently Executive Vice President and 
Chief Financial Officer of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), one of 
the world's leading rare disease companies with a market cap of approximately 
USD30 billion. Vikas joined Alexion in 2005 and is responsible for global 
financial management, information technology, corporate and strategic 
development, treasury, internal audit and investor relations. 
 
Prior to Alexion, Vikas spent 11 years at Bayer AG where he held various 
positions within the company in the United States, Canada, Japan and Germany. 
His last role was Vice President and Chief Financial Officer of Bayer 
Pharmaceuticals Corporation, USA, where he was responsible for financial 
management and strategic planning in North America. 
 
Prior to his time at Bayer AG, Vikas worked at ANZ Bank as a Senior Manager in 
Corporate Banking and at Citibank as an analyst. 
 
Vikas is a chartered accountant by training. He is a certified public 
accountant in the USA, and an associate member of the Institute of Chartered 
Accountants of India. Vikas also has a Master's degree in Business 
Administration from the Asian Institute of Management in the Philippines. 
 
Dr. David Ebsworth, Chairman of Verona Pharma, said: "Vikas' impressive 
financial background, including his US expertise, makes him a very welcome 
addition to our Board of Directors. I have known Vikas for many years having 
worked together at Bayer and hold his impressive track record in high regard. 
We are pleased that Vikas will be joining our Board at such a pivotal time, as 
we progress our lead asset, RPL554, into a Phase 2b clinical trial programme." 
 
Schedule Two information regarding Vikas Sinha 
 
Vikas Sinha holds or has held the following directorships and partnerships in 
the last five years: 
 
Current Directorships memberships:       Past Directorships memberships: 
 
 
Alexion Pharma Holding                   Stemcentrx Inc. 
 
Save for the information disclosed above, there is no other information in 
relation to Vikas required to be disclosed pursuant to Rule 17 and Schedule 2 
(g) of the AIM Rules for Companies. 
 
                                    -Ends- 
 
For further information please contact: 
 
Verona Pharma plc                        Tel: +44 (0) 20 3283 4200 
 
Jan-Anders Karlsson, Chief Executive 
Officer 
 
N+1 Singer                               Tel: +44 (0)20 7496 3000 
 
Aubrey Powell / Jen Boorer 
 
FTI Consulting                           Tel: +44 (0)20 3727 1000 
 
Simon Conway / Stephanie Cuthbert / 
Natalie Garland-Collins 
 
Notes to Editors 
 
About Verona Pharma plc 
 
Verona Pharma plc is a UK-based clinical stage biotech company focused on the 
development of innovative prescription medicines to treat respiratory diseases 
with significant unmet medical needs, such as chronic obstructive pulmonary 
disease (COPD), asthma and cystic fibrosis. 
 
Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase 
2 trials as a nebulised maintenance treatment for COPD patients with moderate 
to severe disease and possibly as a treatment of acute exacerbations of COPD in 
the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor 
and therefore has both bronchodilator and anti-inflammatory effects, which are 
essential to the improvement of patients with COPD and asthma. 
 
Verona Pharma is also building a broader portfolio of RPL554-containing 
products to maximise its benefit to patients and its value. This includes the 
very significant markets for COPD and asthma maintenance therapy. The Company 
is also exploring the potential of the drug in different diseases, such as 
cystic fibrosis, where it is in pre-clinical testing and has recently received 
a Venture and Innovation Award from the Cystic Fibrosis Trust. 
 
 
 
END
(END) Dow Jones Newswires
September 12, 2016 02:00 ET (06:00 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024